The National Hospital for Neurology and Neurosurgery

London, United Kingdom

The National Hospital for Neurology and Neurosurgery

London, United Kingdom
SEARCH FILTERS
Time filter
Source Type

Elekta (EKTA-B.ST) today announced that its Leksell®Vantage™ Stereotactic System*, the company's next-generation system for target localization and coordinate referencing for precision neurosurgery will be highlighted at Elekta booth 2139 at the American Association of Neurological Surgeons (AANS) Annual Meeting, April 22-26 in Los Angeles. Leksell Vantage head frame is constructed of a novel epoxy composite and is designed to improve imaging quality, speed and patient comfort in neurosurgery procedures. Vantage received CE Mark clearance in March 2017 and will be used this month in clinical practice for the first time in Europe at University Hospital La Timone (Marseilles, France), The Academic Medical Center (Amsterdam, the Netherlands), The National Hospital for Neurology and Neurosurgery, Queens Square (London, England) and Karolinska University Hospital (Stockholm, Sweden). The system is currently pending 510(k) clearance with the U.S. Food and Drug Administration. "Our Leksell Stereotactic System has been helping clinicians achieve outstanding patient outcomes for more than 60 years, and Vantage improves upon this gold standard platform to deliver uncompromising accuracy in stereotactic imaging and treatment," says Jesper Söderqvist, Vice President Neuroscience Portfolio at Elekta. "With potential for faster imaging, more efficient workflow, reduced artifacts and a better overall user experience, Leksell Vantage is a welcome advancement for physicians and their patients." Leksell Gamma Knife featured in more than 15 abstracts In addition to Vantage, Elekta will highlight its Leksell Gamma Knife® radiosurgery system. The most clinically studied stereotactic radiosurgery platform, Gamma Knife was highlighted in more than 15 scientific presentations at AANS, including: The posters for Abstracts #1837 and #2022 are available through the AANS conference app. "The inclusion of more than 15 data abstracts at this major neurosurgery conference underscores the fundamental role that Gamma Knife plays today in the treatment of cancer and other complex neurological disorders," says Söderqvist. "These studies also highlight the potential of Gamma Knife to enable the treatment regimens of tomorrow, offering the enhanced radiation targeting and sparing of healthy tissue that is essential for optimum care and outcomes." Additional data presented during the conference (Abstract #2331) confirmed that Elekta's Leksell Gamma Knife was the most frequently mentioned SRS system in a comprehensive clinical literature review with 11,638 citations out of 13,539 articles retrieved. Gamma Knife was also the most frequently cited SRS system in neurosurgical indications, including brain metastases (n=1037), arteriovenous malformation (n=734) and spinal metastases (n=184). For more information on Gamma Knife, visit Elekta booth 2139 at AANS 2017 or www.gammaknife.com. *Leksell® Vantage™ Stereotactic System is pending 510(k) clearance and not available for sale or distribution in the United States. For further information, please contact: Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com Time zone: CET: Central European Time This information was brought to you by Cision http://news.cision.com The following files are available for download: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/elekta-to-highlight-continued-innovation-in-stereotactic-neurosurgery-with-leksell-vantage-stereotactic-system-at-aans-300444156.html


Meir A.,The National Hospital for Neurology and Neurosurgery | Bush K.,The London Clinic
European Spine Journal | Year: 2017

Purpose: To show that with C5 radiculopathy and profound neurological deficit, good outcomes can be obtained with injection therapy. Method: We present two cases of cervical radiculopathy secondary to disc prolapse associated with profound neurological deficit. In both cases, cervical injection therapy was used as the primary management. Results: The two cases presented were both male, 59 and 36 years, and were diagnosed on MRI imaging with C4/5 disc prolapses. They presented with severe motor deficit and were both treated with foraminal epidural steroid injections, one of the patients also had two previous injections elsewhere prior to the first review. In both patients, pain and neurological deficit improved in a timely manner resulting in full recovery. MRI taken after recovery showed complete resorption of the disc prolapse in both cases. Conclusion: In C5 radiculopathy, even with severe neurological deficit, cervical injection therapy should be considered. These cases illustrate that excellent results can be obtained without the need for open surgery with its inherent risks. © 2017 Springer-Verlag Berlin Heidelberg


Stinear C.M.,University of Auckland | Ward N.S.,University College London | Ward N.S.,The National Hospital for Neurology and Neurosurgery
International Journal of Stroke | Year: 2013

Neuroimaging plays an important role in acute stroke diagnosis and management, but it is not routinely used in rehabilitation settings. Incorporating imaging information in rehabilitation planning may eventually translate to better outcomes after stroke. Here we review the prediction of outcomes after stroke using magnetic resonance imaging. There are clear and specific relationships between the anatomy of the stroke lesion and impairments at the time of scanning, and at later time points in recovery. However, most studies demonstrate these relationships in groups of patients at the chronic stage. In order to be useful for rehabilitation, neuroimaging needs to provide prognostic information for individual patients at a much earlier stage. Recent studies have used diffusion tensor imaging and functional neuroimaging to address this, with promising results. Combining neuroimaging with clinical and neurophysiological assessments may also be useful. Future work in this area may support the tailoring of rehabilitation for individual patients based on their capacity for neural reorganization and recovery. © 2012 The Authors. International Journal of Stroke © 2012 World Stroke Organization.


Botcharova M.,University College London | Farmer S.F.,University College London | Farmer S.F.,The National Hospital for Neurology and Neurosurgery | Berthouze L.,University of Sussex | Berthouze L.,University College London
Frontiers in Systems Neuroscience | Year: 2014

The concept of the brain as a critical dynamical system is very attractive because systems close to criticality are thought to maximize their dynamic range of information processing and communication. To date, there have been two key experimental observations in support of this hypothesis: (i) neuronal avalanches with power law distribution of size and (ii) long-range temporal correlations (LRTCs) in the amplitude of neural oscillations. The case for how these maximize dynamic range of information processing and communication is still being made and because a significant substrate for information coding and transmission is neural synchrony it is of interest to link synchronization measures with those of criticality. We propose a framework for characterizing criticality in synchronization based on an analysis of the moment-to-moment fluctuations of phase synchrony in terms of the presence of LRTCs. This framework relies on an estimation of the rate of change of phase difference and a set of methods we have developed to detect LRTCs. We test this framework against two classical models of criticality (Ising and Kuramoto) and recently described variants of these models aimed to more closely represent human brain dynamics. From these simulations we determine the parameters at which these systems show evidence of LRTCs in phase synchronization.We demonstrate proof of principle by analysing pairs of human simultaneous EEG and EMG time series, suggesting that LRTCs of corticomuscular phase synchronization can be detected in the resting state and experimentally manipulated. The existence of LRTCs in fluctuations of phase synchronization suggests that these fluctuations are governed by non-local behavior, with all scales contributing to system behavior. This has important implications regarding the conditions under which one should expect to see LRTCs in phase synchronization. Specifically, brain resting states may exhibit LRTCs reflecting a state of readiness facilitating rapid task-dependent shifts toward and away from synchronous states that abolish LRTCs. © 2014 Botcharova, Farmer and Berthouze.


News Article | February 16, 2017
Site: www.accesswire.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.


Andreou A.P.,University of California at San Francisco | Shields K.G.,The National Hospital for Neurology and Neurosurgery | Goadsby P.J.,University of California at San Francisco | Goadsby P.J.,The National Hospital for Neurology and Neurosurgery
Neurobiology of Disease | Year: 2010

Objective: To study the role of GABA receptors in thalamic relay neurons in the ventroposteromedial (VPM) nucleus of the rat activated by a trigeminovascular nociceptive stimulus in relationship to migraine, and the potential modulation of nociceptive transmission by GABA acting anti-convulsants. Methods: Trigeminovascular nociceptive afferents were identified in the VPM by electrical stimulation of the superior sagittal sinus (SSS), and cell bodies identified by activation with l-glutamate. The effect of GABA, valproate and gabapentin ejection during SSS stimulation and microiontophoresis of l-glutamate was studied. GABA responses were characterized with the selective GABAA and GABAB agonists muscimol and baclofen, respectively, and the antagonists bicuculline (GABAA) and hydroxysaclofen (GABAB). Results: GABA inhibited the response to SSS stimulation and l-glutamate ejection. Both the selective GABAA receptor agonist muscimol, and the GABAB agonist baclofen strongly inhibited the post-synaptic response to l-glutamate. This inhibition could be antagonised by co-ejection of the appropriate antagonist. The post-synaptic inhibitory action of GABA on the cell bodies of third order neurons could be partially antagonised by co-ejection of bicuculline but not by hydroxysaclofen. Valproate inhibited the responses to SSS stimulation and l-glutamate ejection. Bicuculline, but not hydroxysaclofen, was able to antagonise the effect of valproate on both responses to l-glutamate and SSS stimulation. Gabapentin did not alter the responses to l-glutamate and SSS stimulation. Interpretation: These results indicate that GABAA and GABAB receptors on thalamic neurons can modulate trigeminovascular nociceptive transmission in the VPM nucleus. Sodium valproate can inhibit trigeminovascular nociception at the level of VPM through GABAA receptor mechanisms, whereas gabapentin does not alter trigeminovascular nociception. © 2009 Elsevier Inc. All rights reserved.


Akram H.,The National Hospital for Neurology and Neurosurgery | Allibone J.,The National Hospital for Neurology and Neurosurgery
Clinical Oncology | Year: 2010

Malignant spinal cord compression is an important neuro-oncological emergency, the management of which has been changing throughout the last 30 years. We hereby attempt to present an overview of this pathological entity with general management concepts, paying special attention to the palliative surgical treatments available, the decision-making process and the new emerging treatment modalities. © 2010 The Royal College of Radiologists.


Lambru G.,The National Hospital for Neurology and Neurosurgery
Current pain and headache reports | Year: 2013

Primary headache disorders that are more frequently encountered in the paediatric population include migraine and tension-type headaches. The trigeminal autonomic cephalalgias (TACs), which includes cluster headache (CH), paroxysmal hemicrania (PH) and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT), are rarely reported in the paediatric population. The 1-year prevalence of CH seems to be 0.03 %. The clinical features of childhood and adolescence onset CH seem to be similar to those of adult onset. Cranial autonomic features and restlessness seem to less prominent in children than in adults. When restlessness is present, it often manifests as thrashing around in children and can distract attention from the headache, thereby contributing to a delay in diagnosis. The frequency of cluster periods seems to be lower in childhood. Similarly, the duration of the single cluster period seems to be shorter. The temporal pattern shows a trend towards a gradual increase of frequency and duration of symptoms in adult life. In terms of management of paediatric CH, oxygen has been used successfully in several paediatric CH patients, and given its good side-effect profile, it is considered the abortive agent of choice for paediatric CH. Verapamil is the preventative drug of choice in both episodic and chronic CH, though paediatric patients should be started on lower doses and titrated according to age. Paediatric-onset PH and SUNCT are very rarely reported. The clinical phenotype and response to treatment seem to resemble the adult-onset form. Paediatric-onset TACs are poorly recognized and there is often a delay of several months or years before the diagnosis is made. Awareness of typical clinical pictures of these excruciating headaches is essential to allow prompt initiation of the appropriate management.


Schreiber B.E.,Royal Free Hampstead NHS Trust | Agrup C.,University College London | Haskard D.O.,Imperial College London | Luxon L.M.,The National Hospital for Neurology and Neurosurgery
The Lancet | Year: 2010

Sudden sensorineural hearing loss is usually unilateral and can be associated with tinnitus and vertigo. In most cases the cause is not identified, although various infective, vascular, and immune causes have been proposed. A careful examination is needed to exclude life threatening or treatable causes such as vascular events and malignant diseases, and patients should be referred urgently for further assessment. About half of patients completely recover, usually in about 2 weeks. Many treatments are used, including corticosteroids, antiviral drugs, and vasoactive and oxygen-based treatments. Although no treatment is proven, we recommend a short course of oral high-dose corticosteroids. There is much to learn about pathogenesis of sudden sensorineural hearing loss, and more clinical trials are needed to establish evidence-based management. © 2010 Elsevier Ltd. All rights reserved.


News Article | February 16, 2017
Site: marketersmedia.com

TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. TORONTO, ON / ACCESSWIRE / February 16, 2017 / Wi2Wi Corporation (Wi2Wi or the Company) (TSX-V: YTY), announces that Mr. Daniel Phelan has resigned as a director and Chairman of the Board of Directors. Mr. Michael R. Sonnenreich and Fraser C. Henderson Sr., M.D have joined the Board of Directors and Mr. Sonnenreich was elected as the Chairman of the Board of Directors. Mr. Sonnenreich is a lawyer and a philanthropist and has extensive management experiences in various industries; Technology, Pharmaceutical and Global Marketing. He is an active stake holder and advisor to several national and international companies. Currently, Mr. Sonnenreich is the Chairman of the Board of Kikaku America International, and Vice Chairman of PharMa International Corporation of Tokyo, Japan. He is a graduate of the University of Wisconsin, the University of Madrid, Spain, and Harvard University Law School. In the past twelve years Mr. Sonnenreich has served as a board member and trustee of numerous important companies and universities, including Williams Creek Explorations, Vancouver, British Columbia, Canada; Wi2Wi, San Jose, California; Tyhee Development Corp. Ltd., Vancouver, British Columbia, Canada; Les Aliments SoYummi, Inc., Montreal, Canada; the ABD American Capital Market Funds; the Integra Fund; Continental Steel Inc.; Amorfix Life Sciences Ltd. (now Promis Neurosciences), Vancouver, British Columbia, Canada; Scientific American; and Medical Tribune International. Mr. Sonnenreich has had long-term involvement with many nonprofit institutions. These include the Washington National Opera (President 1996-98; 2002-2006); D.C. Jazz Festival (Chairman, 2010-2014); Sackler/Freer Galleries of Art (Smithsonian Institution), D.C.; Commission on the Arts and Humanities (Mayoral Appointment as Commissioner, 2008-2011); the Johns Hopkins University School of Advanced International Studies; the New England Conservatory of Music; the North Carolina Museum of Art Foundation; the University of Virginia Art Museum; Clark University; the Maret School; and the Richard Tucker Music Foundation. Mr. Sonnenreich served as President of the National Coordinating Council on Drug Education. In 2008, he was named Distinguished Washingtonian by the University Club of Washington, D.C. He previously served in government in the Department of Justice and was appointed Executive Director of the National Commission on Marijuana and Drug Abuse. Dr. Henderson is a world renowned Board-certified Neurological Surgeon and a retired US Navy Commander. He has received both his bachelor's and Medical degree from the University of Virginia, Charlottesville Virginia. He completed his fellowship in Craniospinal surgery under Professor Alan Crockard at The National Hospital for Neurology and Neurosurgery, Queen Square, London. As Part of his active duty obligations; Dr. Henderson was the Director of Spine at National Naval Medical Center, Bethesda, MD and was Brigade Neurosurgeon for the 4th Marine Expeditionary Brigade in Desert Shield and Desert Storm during the 1st Gulf War. Finishing his tour with the US Navy, Commander Henderson joined Georgetown University, in Washington D.C. as Director of Neurosurgery of the Spine and Cranio-cervical Junction. He was Co-Director of the Lombardi Neuro-Oncology Division, Co-Director of the CyberKnife Radiosurgery Center, and Medical Director of the Neuroscience Nursing Units. He was Professor of Neurosurgery and Radiology at Georgetown University, where he was active in advancing CyberKnife radiosurgery for treatment of chordoma and other complex spinal tumors. He is the Director of Neurosurgery at Doctors Hospital and Director of the Chiari Center of Excellence, where he is focused on the development of the understanding and treatment of deformity induced injury to the brainstem and spinal cord in Chiari Malformation and Ehlers Danlos Syndrome. Dr. Henderson developed intellectual property for three inventions relating to spinal radiosurgery and spinal cancer, including the TPS® -Telescopic Plate Spacer- a vertebral replacement device for metastatic disease and was Principal Investigator in the translational development of a radio-sensitizing drug, and a drug to block the malignant invasiveness of Glioblastoma Multiforme. He is an inventor of 11 devices and concepts relating to disorders of the brainstem and spinal cord, and has published over 50 peer reviewed articles and book chapters, and given over 120 invited lectures with a focus on craniocervical disorders, Chiari malformation, cancer, radiosurgery and unusual problems of the spine "We are excited to have both Mr. Sonnenreich and Mr. Henderson in the Board. Their vast experience and expertise will definitely guide the company into the successful future," said Zachariah Mathews, President and CEO of Wi2Wi. "The Board expresses its profound appreciation to Mr. Daniel Phelan for the business and financial expertise he brought to the board of directors over the past three years and helping the management of the company," said the Chairman of the Board Mr. Michael Sonnenreich. For further information, please contact: Essentially, IoT and M2M describe the network of physical objects or "things" embedded with electronics, software, sensors, and network connectivity, which enables these objects to collect and exchange data. Driven by several factors including the growth in the availability of Broadband Internet, which reduces the cost of connecting, and the related increase in Wi-Fi capabilities as well as sensors built into myriad technologies, this has been described as the "perfect storm" for the IoT. Almost any device with an on and off switch that can be connected to the Internet (and/or to each other) - anything from cell phones, coffee makers, washing machines, headphones, lamps, wearable devices, cars, as well as machine components in the engine of a jet airplane or the drill of an oil rig. According to analyst firm Gartner, by 2020 there will be over 26 billion connected devices. Others think this figure could be too conservative by a factor of four. Wi2Wi is a vertically-integrated technology company which designs, manufactures and markets high performance, low power wireless connectivity solutions, global navigation satellite system (GNSS) modules, and frequency control devices. The Company's products and services address numerous applications in the markets of Internet of Things (IoT), Machine to Machine (M2M), Avionics, Space, and Government Sponsored Projects. Wi2Wi's products and value-added services provide highly integrated, rugged, robust, and reliable multiprotocol wireless actuators with embedded software, along with customized timing and frequency control devices for customers, worldwide. The Company was founded in 2005 and is strategically headquartered in San Jose, California with satellite offices in Middleton, Wisconsin and Hyderabad, India. Wi2Wi's manufacturing operations, its laboratory for reliability and quality control, together with design and engineering for timing and frequency control devices are located in Middleton, WI. The branch office, located in Hyderabad, India, focuses on the development of wireless connectivity; both hardware and software. Wi2Wi's strategic objective is to service the unique needs of each customer by providing end to end wireless integration solutions and highly customizable timing and frequency control devices. Wi2Wi distinguishes itself from commodity grade products, with best in the market performance, highly reliable, low power wireless connectivity products with integrated software that supports broader temperature ranges and a longer product life cycle. Furthermore, Wi2Wi's end to end product solutions helps the customer substantially reduce their end product expense, certification cost, and overall R&D investment, in addition to substantially reducing the time to market. Wi2Wi has partnered with best in class global leaders in technology, manufacturing, and sales. The Company uses a wide network of manufacturer's representatives, worldwide, to promote its products and services, and has partnered with world class distributors for the fulfillment of orders along with direct sales. Forward-Looking Statements: This news release contains certain forward-looking statements, including management's assessment of future plans and operations, and the timing thereof, that involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. Such risks and uncertainties include, without limitation, risks associated with the ability to access sufficient capital, the impact of general economic conditions in Canada, the United States and overseas, industry conditions, stock market volatility. The Company's actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements and, accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits, including the amount of proceeds, that the Company will derive there from. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on these and other factors that could affect the Company's operations and financial results are included in reports on file with Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com). Forward-looking statements are made based on management's beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements and if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. All subsequent forward-looking statements, whether written or oral, attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Furthermore, the forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Loading The National Hospital for Neurology and Neurosurgery collaborators
Loading The National Hospital for Neurology and Neurosurgery collaborators